Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31248761 | 0.87 | L3MBTL1 (0.52) | CA2CA1NAMPTMEN1KMT2A | |
| SCHEMBL18800977 | 0.81 | NAMPT (0.58) | CA2CA1NAMPTIDO1AKT1 | |
| SCHEMBL20208983 | 0.80 | CA2 (0.55) | LMNACA2CA1NAMPTIDO1 | |
| SCHEMBL5266340 | 0.80 | TDP1 (0.50) | CA2CA1MEN1KMT2AMAPT | |
| SCHEMBL14353181 | 0.80 | L3MBTL1 (0.56) | LMNAMEN1KMT2AL3MBTL1OPRM1 | |
| SCHEMBL23291128 | 0.79 | CYP17A1 (0.59) | LMNACA2CA1NAMPTPTGER4 | |
| SCHEMBL4465651 | 0.78 | MGLL (0.51) | LMNACA2CA1NAMPTKMT2A | |
| SCHEMBL19502096 | 0.78 | CYP17A1 (0.53) | CA1NAMPTGPR119CYP17A1 | |
| SCHEMBL29773322 | 0.77 | BRD4 (0.52) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL20208984 | 0.77 | CTSS (0.50) | CA2CA1NAMPTPTGER4AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415045-B2 | Peripherally acting opioid compounds | ALKERMES, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150196550-A1 | Peripherally Acting Opioid Compounds | ALKERMES INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-8962646-B2 | Peripherally acting opioid compounds | ALKERMES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2725908-A1 | PERIPHERALLY ACTING OPIOID COMPOUNDS | Alkermes, Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013003720-A1 | PERIPHERALLY ACTING OPIOID COMPOUNDS | ALKERMES, INC. (US) | 2013-01-03 | — | — | WO | disclosed |
| US-20130005755-A1 | Peripherally Acting Opioid Compounds | ALKERMES, INC. | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196550-A1 | Peripherally Acting Opioid Compounds | OPRM1, OPRK1, OPRL1 | LMNA 4277/4885CA2 3951/4885CA1 3479/4885 |
| US-20130005755-A1 | Peripherally Acting Opioid Compounds | OPRM1, OPRK1, OPRL1 | LMNA 4277/4885CA2 3951/4885CA1 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.